Loading...
Loading...
Prana
Biotechnology
PRANPBT today reported that it had
received a recommendation from the Data Safety Monitoring Board
(DSMB) that the IMAGINE trial for Alzheimer's disease should continue
as planned based on the initial review of clinical data. The DSMB is
an independent group of experts who review the accumulated safety
data in ongoing clinical trials, in order to safeguard the interests
and safety of participating and future patients. The DSMB considers
study-specific data as well as relevant background knowledge about
the disease, test agent, or patient population under study.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in